Plain-English translation of NCT05241249 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that works by stimulating certain nerves in your body, as a way to help slow pancreatic cancer growth. You would take this medication alongside two standard chemotherapy drugs you'd already receive as part of your cancer treatment plan. The goal is to see whether adding this medication helps shrink your tumor before surgery and keeps cancer from coming back.
Research in animals has shown that this medication may slow cancer growth and spread by affecting how nerves behave inside tumors. Doctors want to test whether this approach could help patients with borderline resectable pancreatic cancer — tumors that are challenging to remove completely — and improve surgery outcomes.
You likely qualify if…
You likely don't qualify if…
You would start taking the medication on day 1 and continue it daily for at least 2 months, stopping 2 days before your scheduled surgery. Throughout this time, you would also receive your standard chemotherapy regimen as planned. The study team will monitor you regularly to check how well you tolerate the medication and how your cancer is responding to the combined treatment.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States